VBI Net Receivables vs Short Term Investments Analysis
VBIV Stock | USD 0.64 0.01 2.03% |
VBI Vaccines financial indicator trend analysis is much more than just breaking down VBI Vaccines prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether VBI Vaccines is a good investment. Please check the relationship between VBI Vaccines Net Receivables and its Short Term Investments accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.
Net Receivables vs Short Term Investments
Net Receivables vs Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of VBI Vaccines Net Receivables account and Short Term Investments. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between VBI Vaccines' Net Receivables and Short Term Investments is -0.18. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of VBI Vaccines, assuming nothing else is changed. The correlation between historical values of VBI Vaccines' Net Receivables and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of VBI Vaccines are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Net Receivables i.e., VBI Vaccines' Net Receivables and Short Term Investments go up and down completely randomly.
Correlation Coefficient | -0.18 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Net Receivables
Short Term Investments
Short Term Investments is an item under the current assets section of VBI Vaccines balance sheet. It contains any investments VBI Vaccines undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that VBI Vaccines can easily liquidate in the marketplace.Most indicators from VBI Vaccines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VBI Vaccines current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.At this time, VBI Vaccines' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 35.9 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.76) in 2024.
2023 | 2024 (projected) | Non Recurring | 5.7M | 5.0M | Reconciled Depreciation | 2.0M | 1.6M |
VBI Vaccines fundamental ratios Correlations
Click cells to compare fundamentals
VBI Vaccines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
VBI Vaccines fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 122.2M | 209.4M | 210.3M | 155.1M | 87.0M | 73.5M | |
Total Stockholder Equity | 88.3M | 171.7M | 143.9M | 64.2M | 7.5M | 7.2M | |
Property Plant And Equipment Net | 10.2M | 10.7M | 11.0M | 12.3M | 11.9M | 21.9M | |
Net Debt | (29.4M) | (92.9M) | (89.9M) | (10.4M) | 29.4M | 30.8M | |
Retained Earnings | (262.4M) | (308.6M) | (378.4M) | (489.6M) | (582.4M) | (553.3M) | |
Cash | 44.2M | 93.8M | 121.7M | 62.6M | 23.7M | 28.9M | |
Non Current Assets Total | 75.2M | 77.3M | 80.0M | 77.4M | 50.7M | 42.9M | |
Non Currrent Assets Other | 2.1M | 2.2M | 4.6M | 4.7M | 1.2M | 992.6K | |
Cash And Short Term Investments | 44.2M | 119.1M | 121.7M | 62.6M | 23.7M | 31.5M | |
Common Stock Shares Outstanding | 4.0M | 7.3M | 8.5M | 8.6M | 15.6M | 16.4M | |
Liabilities And Stockholders Equity | 122.2M | 209.4M | 210.3M | 155.1M | 87.0M | 73.5M | |
Other Current Assets | 450K | 1.3M | 2.2M | 8.4M | 2.8M | 2.9M | |
Other Stockholder Equity | 66.4M | 75.5M | 81.6M | 90.0M | 107.4M | 112.8M | |
Total Liab | 33.9M | 37.7M | 66.4M | 90.9M | 79.4M | 83.4M | |
Property Plant And Equipment Gross | 11.7M | 12.3M | 19.3M | 23.6M | 22.3M | 27.7M | |
Total Current Assets | 47.0M | 132.0M | 130.3M | 77.7M | 36.2M | 33.0M | |
Total Current Liabilities | 29.8M | 17.3M | 32.6M | 36.9M | 75.7M | 79.5M | |
Accounts Payable | 1.1M | 3.7M | 4.3M | 13.0M | 6.4M | 6.8M | |
Net Receivables | 201K | 77K | 8K | 94K | 1.3M | 1.3M | |
Non Current Liabilities Total | 4.2M | 20.3M | 33.8M | 54.0M | 3.7M | 3.5M | |
Accumulated Other Comprehensive Income | (752K) | 1.3M | (1.6M) | 21.4M | 28.3M | 29.7M | |
Other Assets | 620K | 2.2M | 1.3M | 1.4M | 1.0 | 0.95 | |
Short Long Term Debt Total | 14.8M | 944K | 31.8M | 52.2M | 53.0M | 55.7M | |
Inventory | 1.1M | 2.2M | 2.6M | 6.6M | 8.5M | 8.9M | |
Other Current Liab | 12.9M | 12.4M | 26.9M | 22.6M | 6.7M | 5.7M | |
Short Term Debt | 14.8M | 944K | 839K | 972K | 51.7M | 54.3M | |
Common Stock Total Equity | 285.0M | 403.5M | 442.2M | 442.3M | 508.7M | 260.5M | |
Common Stock | 285.0M | 403.5M | 442.2M | 442.3M | 454.2M | 247.1M | |
Net Tangible Assets | 25.3M | 107.3M | 79.5M | 3.7M | 4.2M | 4.0M | |
Current Deferred Revenue | 882K | 255K | 526K | 409K | 10.9M | 11.4M | |
Intangible Assets | 60.8M | 62.2M | 62.1M | 58.3M | 36.5M | 47.5M | |
Property Plant Equipment | 11.7M | 10.7M | 11.0M | 12.3M | 14.1M | 14.8M | |
Other Liab | 3.4M | 3.4M | 2.9M | 2.7M | 3.1M | 2.7M | |
Short Long Term Debt | 1.6M | 1.1M | 14.8M | 50.8M | 58.4M | 61.3M | |
Capital Surpluse | 66.4M | 75.5M | 81.6M | 90.0M | 103.5M | 75.2M | |
Good Will | 8.3M | 2.2M | 2.3M | 2.1M | 1.1M | 1.1M | |
Retained Earnings Total Equity | (262.4M) | (308.6M) | (378.4M) | (489.6M) | (440.6M) | (418.6M) |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
CEOs Directory Screen CEOs from public companies around the world |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.03) | Revenue Per Share 0.558 | Quarterly Revenue Growth 1.911 | Return On Assets (0.29) | Return On Equity (2.59) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.